What is Exenatide used for in research?

Research on Exenatide has focused on: Improves glycemic control; Promotes weight loss; Slows gastric emptying; Reduces HbA1c by 0.8-1.5%; Cardiovascular benefits; Available in multiple formulations.

What is the typical dose of Exenatide?

Typical research doses are 5-10 mcg (twice daily) or 2 mg (weekly) mcg, administered twice daily or once weekly. Commonly timed: Before meals (short-acting). These are research figures only — not clinical recommendations.

What are the known side effects of Exenatide?

Side effects reported in research include: Nausea (common, mild); Vomiting (uncommon, moderate); Diarrhea (uncommon, mild); Constipation (uncommon, mild); Headache (uncommon, mild); Dizziness (uncommon, mild); Hypoglycemia (Low Blood Glucose) (uncommon, serious); Injection Site Reactions (uncommon, mild); Lipodystrophy (Localized Fat Loss or Thickening) (uncommon, mild); Pancreatitis (Acute Inflammation of the Pancreas) (rare, serious); Thyroid C-Cell Proliferation (Animal Studies) (rare, serious); Acute Kidney Injury (rare, serious); Allergic Reactions (rare, serious); Delayed Gastric Emptying (uncommon, moderate); Appetite Suppression (common, mild). Always consult a qualified professional before use.

How is Exenatide administered?

Exenatide is typically administered via Subcutaneous.

Can Exenatide be injected?

In the research literature, Exenatide is described with subcutaneous administration. This is research information only, not medical advice.

What is the evidence quality for Exenatide?

Exenatide carries an evidence grade of A. Grade A — supported by human randomised controlled trials.

Metabolic & Weight Loss / Subcutaneous

Exenatide

Q: How do you reconstitute Exenatide?

With 5 mg in the vial, the water you add changes the draw. Mixed with 1 mL that is 5,000 mcg per mL, so on a U-100 syringe 5 mcg is 0.1 units and 10 mcg is 0.2 units. Mixed with 2 mL it is 2,500 mcg per mL, so 5 mcg is 0.2 units and 10 mcg is 0.4 units. Use bacteriostatic water, swirl gently rather than shaking, and keep the mixed vial in the fridge. Research use only.

Also known as Byetta, Bydureon

Exenatide is the first GLP-1 receptor agonist approved by the FDA. Based on exendin-4 from Gila monster saliva, it is available as twice-daily or once-weekly formulation for type 2 diabetes and weight management.

What is Exenatide used for? Research has focused on improves glycemic control; promotes weight loss; slows gastric emptying.

Compare with other peptides studied forfat loss,muscle growth

Evidence grade AFDA approved

Exenatide injection at a glance

Figures from the published research literature. Research use only.

Dose range: 5-10 mcg (twice daily) or 2 mg (weekly)
Route: Subcutaneous

How often, when, and the dosing notes are in the dosing reference further down.

Work out your units in the free calculator

Beginner basics

Plain-English guide to Exenatide

What it does: Exenatide helps your body control blood sugar levels and reduces appetite by mimicking a hormone your gut naturally makes. Researchers use it to help with weight loss and blood sugar management.
Typical dose: Researchers typically use 5-10 micrograms injected under the skin twice daily, or 2 milligrams once per week, depending on the formulation chosen.
When to inject: For the twice-daily version, inject before meals. The once-weekly version can be taken any day of the week at the same time.
Storage: Keep the powder in the refrigerator (don't freeze it). Once mixed with water, keep it refrigerated and use within the timeframe on your package instructions.
Beginner tip: Start with the lowest dose and give your body a week or two to adjust before increasing-most people experience mild nausea at first that typically goes away.

Research status

Evidence grade A: Large human randomised controlled trials, or approved by the FDA or another major authority.
FDA approved: Approved by the US Food and Drug Administration for at least one indication.

FDA-approved for type 2 diabetes

For research purposes only. Not approved for human use. Not medical advice.

Research areas

Improves glycemic control
Promotes weight loss
Slows gastric emptying
Reduces HbA1c by 0.8-1.5%
Cardiovascular benefits
Available in multiple formulations

Side effects

Effect	How often	Severity
NauseaMost common side effect, especially during the first 1-2 weeks of treatment. Usually resolves with continued use as the body adapts. Occurs in 40-50% of users. Manage by taking doses with food, staying hydrated, and eating small, frequent meals. Antiemetics (e.g., ginger, vitamin B6) may help.	Common	Mild
VomitingOccurs in 5-10% of users, typically early in treatment. If severe or persistent, contact a healthcare provider. May indicate need for dose adjustment or temporary discontinuation.	Uncommon	Moderate
DiarrheaOccurs in 5-10% of users. Usually self-resolving within days to weeks. Manage with adequate hydration and dietary fiber. Avoid high-fat foods which may exacerbate symptoms.	Uncommon	Mild
ConstipationOccurs in 5-10% of users. Manage with increased water intake, dietary fiber, and physical activity. Stool softeners may be used if needed.	Uncommon	Mild
HeadacheOccurs in 5-10% of users. Usually mild and self-resolving. Over-the-counter analgesics (acetaminophen, ibuprofen) may be used if needed.	Uncommon	Mild
DizzinessOccurs in 5-10% of users, particularly if blood glucose drops rapidly. Ensure adequate carbohydrate intake and monitor blood glucose regularly. Rise slowly from sitting or lying positions.	Uncommon	Mild
Hypoglycemia (Low Blood Glucose)Risk is increased when exenatide is combined with insulin or sulfonylureas. Symptoms include tremor, sweating, palpitations, anxiety, confusion, and loss of consciousness. Always carry fast-acting carbohydrates (glucose tablets, juice). Requires immediate medical attention if severe. Dose adjustment of concurrent medications may be necessary.	Uncommon	Serious
Injection Site ReactionsRedness, swelling, or itching at injection site occurs in 5-10% of users. Manage by rotating injection sites, using proper injection technique, and allowing the solution to reach room temperature before injection. Topical antihistamines may help itching.	Uncommon	Mild
Lipodystrophy (Localized Fat Loss or Thickening)Occurs with repeated injections in the same area. Prevent by rotating injection sites systematically and maintaining at least 1 inch between injection points. This is a cosmetic concern but can affect absorption if severe.	Uncommon	Mild
Pancreatitis (Acute Inflammation of the Pancreas)Rare but serious adverse event reported in clinical trials and post-marketing surveillance. Symptoms include severe upper abdominal pain, back pain, nausea, and vomiting. Requires immediate emergency medical evaluation. Discontinue exenatide immediately if pancreatitis is suspected. History of pancreatitis is a relative contraindication.	Rare	Serious
Thyroid C-Cell Proliferation (Animal Studies)Animal studies showed dose-dependent thyroid C-cell proliferation and medullary thyroid carcinoma at high doses. Clinical relevance in humans is unclear, but exenatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).	Rare	Serious
Acute Kidney InjuryRare cases reported, particularly in patients with pre-existing renal impairment or severe dehydration. Monitor renal function and ensure adequate hydration. Use with caution in patients with eGFR <30 mL/min/1.73m².	Rare	Serious
Allergic ReactionsRare but serious. Symptoms include rash, urticaria, angioedema, dyspnea, and anaphylaxis. Requires immediate emergency medical attention. Discontinue exenatide immediately if allergic reaction occurs.	Rare	Serious
Delayed Gastric EmptyingExenatide slows gastric emptying as part of its mechanism, but severe gastroparesis is rare. Symptoms include persistent nausea, vomiting, and abdominal bloating. Monitor for worsening GI symptoms; dose adjustment or discontinuation may be necessary.	Uncommon	Moderate
Appetite SuppressionIntentional effect of exenatide that contributes to weight loss. However, excessive appetite suppression may lead to inadequate caloric intake. Ensure balanced nutrition and monitor for signs of malnutrition.	Common	Mild

Dosing reference

Dose scale from the research

Starting: 5 mcg
Upper end: 10 mcg

Exenatide dosing reference
Parameter	Value
Dose range	5-10 mcg (twice daily) or 2 mg (weekly)
Frequency, timing and route are for members Sign up free Log in

Checked October 2026

Research disclaimer. Figures are drawn from published research literature and community logs. They are not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration

Worked example

With 5 mg in the vial, the water you add changes the draw. Mixed with 1 mL that is 5,000 mcg per mL, so on a U-100 syringe 5 mcg is 0.1 units and 10 mcg is 0.2 units. Mixed with 2 mL it is 2,500 mcg per mL, so 5 mcg is 0.2 units and 10 mcg is 0.4 units.

Work out your exact dose in the free peptide calculator

Storage and stability

Refrigerate. Do not freeze.

Molecular and pharmacological data

Molecular weight	4186 Da
Half-life	2.4 hours (short-acting); 7 days (extended-release weekly formulation)
Sequence	Members only

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1, which regulates blood glucose and appetite. It works by stimulating insulin secretion in response to elevated blood glucose, slowing gastric emptying to reduce postprandial glucose spikes, and promoting satiety through central nervous system signaling. These combined effects improve glycemic control and reduce body weight in patients with type 2 diabetes and obesity.

Pathways and mechanism detail are for members

Keep a log of your Exenatide research

Free account. No credit card required.

Start free Goal finder Interaction checker

Research citations

2 sources

Exenatide clinical trials
GLP-1 agonist mechanisms

All Metabolic & Weight Loss peptides

Browse the research library

147 peptide profiles and 59 blend profiles with mechanism summaries, dosing data and reconstitution guides.

View all peptides

Stay updated on Exenatide research

A weekly digest of new peptide research, stack guides and site updates.

Research use only. All content on this page is provided for informational and educational purposes related to scientific research. Exenatide is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.